Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

Cancer Treatment Reviews

Volumn 37, Issue 6, 2011, Pages 456-464

  Giaccone, Giuseppe ^a   Wang, Yisong ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Afatinib; BIBW 2992; Epidermal growth factor receptor; Non small cell lung cancer; PF 00299804; Resistance; Tyrosine kinase inhibitor

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AFATINIB; BMS 690514; CETUXIMAB; CRIZOTINIB; DACOMITINIB; DN 30; DOCETAXEL; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; K RAS PROTEIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; NERATINIB; PACLITAXEL; PLACEBO; RETASPIMYCIN; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TIVANTINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; XL 184; XL 647;

ABDOMINAL PAIN; ACNE; ACRODERMATITIS; ACUTE KIDNEY FAILURE; ANEMIA; ANOREXIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DIARRHEA; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG POTENCY; DYSPNEA; FATIGUE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; NAUSEA; NONHUMAN; POINT MUTATION; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANIMALS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 79960986318     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.01.003     Document Type: Review

References (96)

1. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5(5):341-354.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. V.2.2010. [accessed April 8, 2010]. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
3. Sequist L.V. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 2007, 12(3):325-330.
4. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) corrected. J Clin Oncol 2003, 21(12):2237-2246.
5. Heymach J.V., Nilsson M., Blumenschein G., Papadimitrakopoulou V., Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 2006, 12(14 Pt 2):4441s-4445s.
6. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290(16):2149-2158.
7. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
8. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101(36):13306-13311.
9. Miller V.A., Riely G.J., Zakowski M.F., et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008, 26(9):1472-1478.
10. Yang C.H., Yu C.J., Shih J.Y., et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008, 26(16):2745-2753.
11. Zhu C.Q., da Cunha S.G., Ding K., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26(26):4268-4275.
12. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
13. Jackman D.M., Miller V.A., Cioffredi L.A., et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009, 15(16):5267-5273.
14. Rosell R., Moran T., Queralt C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10):958-967.
15. Inoue A., Kobayashi K., Usui K., et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009, 27(9):1394-1400.
16. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
17. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
18. Suda K., Onozato R., Yatabe Y., Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival?. J Thorac Oncol 2009, 4(1):1-4.
19. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7(3):169-181.
20. Inukai M., Toyooka S., Ito S., et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006, 66(16):7854-7858.
21. Maheswaran S., Sequist L.V., Nagrath S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359(4):366-377.
22. Balak M.N., Gong Y., Riely G.J., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12(21):6494-6501.
23. Bean J., Riely G.J., Balak M., et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008, 14(22):7519-7525.
24. Pao W., Wang T.Y., Riely G.J., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2(1):e17.
25. Mitsudomi T., Steinberg S.M., Oie H.K., et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991, 51(18):4999-5002.
26. Rodenhuis S., van de Wetering M.L., Mooi W.J., Evers S.G., van Z.N., Bos J.L. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987, 317(15):929-935.
27. Camp E.R., Summy J., Bauer T.W., Liu W., Gallick G.E., Ellis L.M. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005, 11(1):397-405.
28. Hirsch F.R., Dziadziuszko R., Varella-Garcia L., et al. Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naïve advanced NSCLC: correlation of biomarker status and clinical benefit. J Clin Oncol 2009, 27(15S):8026.
29. Miller V.A., Wakelee H.A., Lara P.N., et al. Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: preliminary results of a phase II trial. J Clin Oncol 2008, 26(15S):8028.
30. Eberhard D.A., Johnson B.E., Amler L.C., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23(25):5900-5909.
31. Massarelli E., Varella-Garcia M., Tang X., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13(10):2890-2896.
32. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039-1043.
33. Bean J., Brennan C., Shih J.Y., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104(52):20932-20937.
34. Cappuzzo F., Janne P.A., Skokan M., et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009, 20(2):298-304.
35. Zucali P.A., Ruiz M.G., Giovannetti E., et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008, 19(9):1605-1612.
36. Viloria-Petit A., Crombet T., Jothy S., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001, 61(13):5090-5101.
37. Ciardiello F., Bianco R., Caputo R., et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004, 10(2):784-793.
38. Chakravarti A., Loeffler J.S., Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62(1):200-207.
39. Jones H.E., Gee J.M., Taylor K.M., et al. Development of strategies for the use of anti-growth factor treatments. Endocr Relat Cancer 2005, 12(Suppl. 1):S173-S182.
40. Hurbin A., Dubrez L., Coll J.L., Favrot M.C. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J Biol Chem 2002, 277(51):49127-49133.
41. Thomson S., Buck E., Petti F., et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005, 65(20):9455-9462.
42. Mazzone M., Comoglio P.M. The Met pathway: master switch and drug target in cancer progression. FASEB J 2006, 20(10):1611-1621.
43. Yauch R.L., Januario T., Eberhard D.A., et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005, 11(24 Pt. 1):8686-8698.
44. Witta S.E., Gemmill R.M., Hirsch F.R., et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006, 66(2):944-950.
45. Yun C.H., Mengwasser K.E., Toms A.V., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008, 105(6):2070-2075.
46. Kwak E.L., Sordella R., Bell D.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005, 102(21):7665-7670.
47. Li D., Ambrogio L., Shimamura T., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27(34):4702-4711.
48. Engelman J.A., Zejnullahu K., Gale C.M., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67(24):11924-11932.
49. Yang C, Shih J, Su W, et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). In: Presented at: 46th annual meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL.
50. Yang C., Shih J., Su W., et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-LUNG 2). Ann Oncol 2010, 21(Suppl. 8):viii123.
51. Miller V.A., Hirsh V., Cadranel J., et al. Phase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2)+best supportive care (BSC) versus placebo+BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-LUNG 1). Ann Oncol 2010, 21(Suppl. 8):viii1.
52. De Greve J, Decoster L, De Mey J, et al. Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2/neu. In: Presented at: the 2nd European lung cancer conference, April 28-May 1, 2010, Geneva, Switzerland.
53. Regales L., Gong Y., Shen R., et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009, 119(10):3000-3010.
54. Gonzales A.J., Hook K.E., Althaus I.W., et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008, 7(7):1880-1889.
55. Janne P.A., Reckamp K., Koczywas M., et al. A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results. J Thorac Oncol 2009, 4(9 Suppl. 1):S293-S294.
56. Mok T., Spigel D.R., Park K., et al. Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(15s):7537.
57. Boyer MJ, Blackhall FH, Park K, et al. Efficacy and Safety of PF299804 Versus Erlotinib: A global, randomized phase 2 trial in patients with advanced non-small cell lung cancer after failure of chemotherapy. In: Oral presentation at: the 46th annual meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL, USA.
58. Campbell A., Reckamp K.L., Camidge D.R., et al. PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): a phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). J Clin Oncol 2010, 28(15s):7596.
59. Park K, Heo DS, Cho BC, et al. PF299804 in Asian patients with non-small cell lung cancer refractory to chemotherapy and erlotinib or gefitnib: A phase I/II study. In: Oral presentation at: the 46th annual meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL, USA.
60. Ross H.J., Blumenschein G.R., Aisner J., et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 2010, 16(6):1938-1949.
61. Smylie M., Blumenschein G., Dowlati A., et al. A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history. J Clin Oncol 2007, 25(18S):412s.
62. Sequist L.V., Besse B., Lynch T.J., et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(18):3076-3083.
63. Ito Y., Hatake K., Takahashi S., et al. Tolerability and safety of oral neratinib (HKI-272) in Japanese patients with advanced solid tumors. J Clin Oncol 2009, 27(15S):e14505.
64. Medina P.J., Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008, 30(8):1426-1447.
65. Swaby R., Blackwell K., Jiang Z., et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. J Clin Oncol 2009, 27(15S):1004.
66. Wong K.K., Fracasso P.M., Bukowski R.M., et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009, 15(7):2552-2558.
67. Godin-Heymann N., Ulkus L., Brannigan B.W., et al. The T790M " gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 2008, 7(4):874-879.
68. Herbst R.S., Sun Y., Korfee S., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advance non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 2009, 27(Suppl.):807s.
69. Bahleda R., Soria J.C., Harbison C.T., et al. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. J Clin Oncol 2009, 27(15S):431s.
70. De Boer R., Arrieta O., Gottfried M., et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009, 27(Suppl.):409s.
71. Herbst R.S., Sun Y., Eberhardt W.E., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11(7):619-626.
72. Natale R.B., Thongprasert S., Greco F.A., et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009, 27(15S):409s.
73. Lee J., Hirsh V., Park K., et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2010, 28(15s):7525.
74. AstraZeneca. AstraZeneca Annual Report 2009. Therapy area review: Oncology: Cancer. [accessed April 14, 2010]. http://www.astrazeneca-annualreports.com/2009/directors_report/therapy_area_review/oncology/index.html.
75. Wakelee H.A., Fehling J.M., Molina J.R., et al. A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies. J Clin Oncol 2008, 26(15S):3528.
76. Rizvi N.A., Kris M.G., Miller V.A., et al. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: results from phase 2. J Clin Oncol 2008, 26(15S):8053.
77. Mekhail T., Rich T., Rosen L., et al. Final results: a dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors. J Clin Oncol 2009, 27(15S):3548.
78. Yap T.A., Frentzas S., Tunariu N., et al. Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition. J Clin Oncol 2009, 27(15S):3523.
79. Laux I., Goldman J., Just R., et al. Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib. J Clin Oncol 2009, 27(15S):3549.
80. Schiller J.H., Akerley W.L., Brugger W., et al. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(7S):LBA7502.
81. Janne PA, Wax M, Leach J, Shankar G, Engelman J. Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design. In: Presented at: the AACR-NCI-EORTC international conference, molecular targets and cancer therapeutics, discovery, biology, and clinical applications, October 21-24, 2008; Geneva, Switzerland.
82. Jin H., Yang R., Zheng Z., et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008, 68(11):4360-4368.
83. Burgess T., Coxon A., Meyer S., et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006, 66(3):1721-1729.
84. Kim K.J., Wang L., Su Y.C., et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006, 12(4):1292-1298.
85. Martens T., Schmidt N.O., Eckerich C., et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006, 12(20 Pt. 1):6144-6152.
86. Shaw A.T., Yeap B.Y., Mino-Kenudson M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27(26):4247-4253.
87. Bang Y., Kwak E.L., Shaw A.T., et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(18S):3.
88. Wong D.W., Leung E.L., So K.K., et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115(8):1723-1733.
89. Hewish M., Chau I., Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 2009, 4(1):54-72.
90. Karp D.D., Paz-Ares L.G., Novello S., et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009, 27(15):2516-2522.
91. Karp D.D., Pollak M.N., Cohen R.B., et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751, 871) in combination with paclitaxel and carboplatin. J Thorac Oncol 2009, 4(11):1397-1403.
92. Jassem J., Langer C.J., Karp D.D., et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(15s):7500.
93. Shimamura T., Li D., Ji H., et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008, 68(14):5827-5838.
94. Soria J.C., Shepherd F.A., Douillard J.Y., et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009, 20(10):1674-1681.
95. Papadimitrakopoulou VA, Malik S, Brown MP, et al. Everolimus (RAD001C) in combination with carboplatin (C) and paclitaxel (P) as first line treatment for patients (pts) with advanced NSCLC: a phase I trial. In: Presented at: the 13th world conference on lung cancer; July 29-August 4, 2009; San Francisco, CA.
96. Leighl N.B., Soria J., Bennouna J., et al. Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(15S):7524.